These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 34390608

  • 1. Therapeutic approach with squaric acid dibutylester for steroid resistant-alopecia areata incognita: A pilot study of a single center.
    Starace M, Vezzoni R, Alessandrini A, Bruni F, Carpanese MA, Misciali C, Sechi A, Piraccini BM.
    Dermatol Ther; 2021 Sep; 34(5):e15096. PubMed ID: 34390608
    [Abstract] [Full Text] [Related]

  • 2. Topical squaric acid dibutylester therapy for alopecia areata: a double-sided patient-controlled study.
    Chua SH, Goh CL, Ang CB.
    Ann Acad Med Singap; 1996 Nov; 25(6):842-7. PubMed ID: 9055014
    [Abstract] [Full Text] [Related]

  • 3. Effect of topical immunotherapy with squaric acid dibutylester for alopecia areata in Japanese patients.
    Sakai K, Fukushima S, Mizuhashi S, Jinnin M, Makino T, Inoue Y, Ihn H.
    Allergol Int; 2020 Apr; 69(2):274-278. PubMed ID: 31767273
    [Abstract] [Full Text] [Related]

  • 4. Seventeen cases of alopecia areata: combination of SADBE topical immunotherapy with other therapies.
    Morita K, Nakamura M, Nagamachi M, Kishi T, Miyachi Y.
    J Dermatol; 2002 Oct; 29(10):661-4. PubMed ID: 12433000
    [Abstract] [Full Text] [Related]

  • 5. Topical therapy of alopecia areata with squaric acid dibutylester.
    Case PC, Mitchell AJ, Swanson NA, Vanderveen EE, Ellis CN, Headington JT.
    J Am Acad Dermatol; 1984 Mar; 10(3):447-50. PubMed ID: 6725657
    [Abstract] [Full Text] [Related]

  • 6. Modified immunotherapy for alopecia areata.
    Yoshimasu T, Furukawa F.
    Autoimmun Rev; 2016 Jul; 15(7):664-7. PubMed ID: 26932732
    [Abstract] [Full Text] [Related]

  • 7. Successful treatment of alopecia areata-like hair loss with the contact sensitizer squaric acid dibutylester (SADBE) in C3H/HeJ mice.
    Freyschmidt-Paul P, Sundberg JP, Happle R, McElwee KJ, Metz S, Boggess D, Hoffmann R.
    J Invest Dermatol; 1999 Jul; 113(1):61-8. PubMed ID: 10417620
    [Abstract] [Full Text] [Related]

  • 8. Treatment of severe alopecia areata with squaric acid dibutylester in pediatric patients.
    Orecchia G, Malagoli P, Santagostino L.
    Pediatr Dermatol; 1994 Mar; 11(1):65-8. PubMed ID: 8170854
    [Abstract] [Full Text] [Related]

  • 9. Squaric acid dibutyl ester for the treatment of alopecia areata: A retrospective evaluation.
    Losol E, Şentürk N.
    Dermatol Ther; 2021 Jan; 34(1):e14726. PubMed ID: 33377267
    [Abstract] [Full Text] [Related]

  • 10. Alopecia Areata Incognita and Diffuse Alopecia Areata: Clinical, Trichoscopic, Histopathological, and Therapeutic Features of a 5-Year Study.
    Alessandrini A, Starace M, Bruni F, Brandi N, Baraldi C, Misciali C, Fanti PA, Piraccini BM.
    Dermatol Pract Concept; 2019 Oct; 9(4):272-277. PubMed ID: 31723460
    [Abstract] [Full Text] [Related]

  • 11. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
    Kagami S, Kishi Y, Hino H.
    J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
    [Abstract] [Full Text] [Related]

  • 12. Squaric acid sensitization is not required for response in the treatment of alopecia areata.
    Vedak P, Kroshinsky D.
    J Am Acad Dermatol; 2015 Sep; 73(3):471-6. PubMed ID: 26282797
    [Abstract] [Full Text] [Related]

  • 13. Topical immunomodulator therapy with squaric acid dibutylester (SADBE) is effective treatment for severe alopecia areata (AA): results of an open-label, paired-comparison, clinical trial.
    Dall'oglio F, Nasca MR, Musumeci ML, La Torre G, Ricciardi G, Potenza C, Micali G.
    J Dermatolog Treat; 2005 Feb; 16(1):10-4. PubMed ID: 15897160
    [Abstract] [Full Text] [Related]

  • 14. Discoid lupus erythematosus exacerbated by contact dermatitis caused by use of squaric acid dibutylester for topical immunotherapy in a patient with alopecia areata.
    Shimaoka Y, Hatamochi A, Hamasaki Y, Suzuki H, Ikeda H, Yamazaki S.
    J Dermatol; 2008 Mar; 35(3):151-3. PubMed ID: 18346258
    [Abstract] [Full Text] [Related]

  • 15. Treatment of alopecia areata with squaric acid dibutylester.
    Micali G, Cicero RL, Nasca MR, Sapuppo A.
    Int J Dermatol; 1996 Jan; 35(1):52-6. PubMed ID: 8838932
    [Abstract] [Full Text] [Related]

  • 16. Topical immunotherapy in alopecia areata.
    Singh G, Lavanya M.
    Int J Trichology; 2010 Jan; 2(1):36-9. PubMed ID: 21188022
    [Abstract] [Full Text] [Related]

  • 17. Normalisation of hair follicle morphology in C3H/HeJ alopecia areata mice after treatment with squaric acid dibutylester.
    Gardner S, Freyschmidt-Paul P, Hoffmann R, Sundberg JP, Happle R, Lindsey NJ, Tobin DJ.
    Eur J Dermatol; 2000 Aug; 10(6):443-50. PubMed ID: 10980465
    [Abstract] [Full Text] [Related]

  • 18. Angioedema After Squaric Acid Treatment in a 6-Year-Old Girl.
    Chen CA, Carlberg V, Kroshinsky D.
    Pediatr Dermatol; 2017 Jan; 34(1):e44-e46. PubMed ID: 27699860
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of the topical sensitizer squaric acid dibutyl ester in Alopecia areata and factors influencing the outcome.
    Ajith C, Gupta S, Kanwar AJ.
    J Drugs Dermatol; 2006 Mar; 5(3):262-6. PubMed ID: 16573260
    [Abstract] [Full Text] [Related]

  • 20. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
    Brown L, Skopit S.
    J Drugs Dermatol; 2018 Aug 01; 17(8):914-917. PubMed ID: 30124734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.